A short report on clinical evaluation of RIX4414: highlights of world-wide development.
De Vos
B
B
GlaxoSmithKline Biologicals, 1330 Rixensart, Belgium. beatrice.de-vos@gskbio.com
Delem
A
A
Hardt
K
K
Bock
H L
HL
Meurice
F
F
Innis
B
B
D000914:Antibodies, Viral / Q000032:analysis; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D018849:Controlled Clinical Trials as Topic; D004311:Double-Blind Method; D005759:Gastroenteritis / Q000453:epidemiology / Q000517:prevention & control*; D006801:Humans; D007070:Immunoglobulin A / Q000032:analysis; D012401:Rotavirus / Q000276:immunology*; D012400:Rotavirus Infections / Q000276:immunology / Q000517:prevention & control*; D022243:Rotavirus Vaccines / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology; D014613:Vaccines, Attenuated / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology
D000914:Antibodies, Viral; D007070:Immunoglobulin A; C492457:RIX4414 vaccine; D022243:Rotavirus Vaccines; D014613:Vaccines, Attenuated